A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)

Trial Profile

A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2015

At a glance

  • Drugs RHIgM22 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 07 Oct 2015 Results of new analysis of pharmacokinetic data from this trial will be presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), according to Acorda Therapeutics media release.
    • 22 Apr 2015 Results were presented at the 67th American Academy of Neurology Annual Meeting, according to an Acorda Therapeutics media release.
    • 22 Apr 2015 Results published in Acorda Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top